tbuckley/cabot-search huggingface dataset:
Retrospective analysis of post-TKI everolimus therapy for metastatic renal cell carcinoma using the doubling-time of tumor growth.
Authors: Yasushi Yoshino, Naoto Sassa, Yasushito Funahashi, Masashi Kato, Takashi Fujita, Yoshihisa Matsukawa, Tokunori Yamamoto, Momokazu Gotoh, Yuichi Ando
Journal: Journal of Clinical Oncology (2014)

e15574 Background: We retrospectively analyzed the effectiveness of post-TKI everolimus for metastatic renal cell carcinoma (RCC) using the doubling-time of the tumor which may presents the activity of the tumor growth during the previous treatment. Methods: Everolimus was administered for a total of 22 patients with metastatic RCC between May 2010 and July 2013 for second-line (6 patients) or further (3rd in 11, 4th in 4 and 5th in 1) regimen of treatment. Median patient age was 67 (range: 29-83), the number of male patient was 16, MSKCC intermediate risk in 16 and 17 underwent prior nephrectomy. The most dominant histology was clear cell carcinoma in 20. The most often metastatic site was lung in 18 which were followed by bone in 11, liver in 6 and lymph node in 2. The doubling- time (DT) was calculated by measuring the tumor in maximal diameter comparing the tumor size in same region [both minimal size (T1) and just before sequence during previous regimen(T2)] [(DT (day) = T2-1(day) x log2 / [3 x log (T2 mm / T1 mm)]. Results: Median overall survival (OS) from initial diagnosis was 50 months, OS after induction of everolimus was 274 days, and progression-free survival (PFS) during everolimus therapy was 148 days. The doubling-time of the main tumor during previous regimen was 396 days. There were no relationship between the time for previous regimens before everolimus and DT (p=0.45 r=0.17). When the patients were divided into 2 group (group A: slow DT, DT=396 days or longer, group B: rapid DT, DT<396 days), PFS of group A was 201 days which was not significant comparing with PFS of 140 days in group B (p=0.325). Overall survival of group A was 827 days which was also not significant comparing with OS of 195 days in group B (p=0.110). The time for previous treatment, the number of previous regimen, previous cytokine therapy and previous nephrectomy did not impact on PFS and OS after induction of everolimus. Conclusions: Tumor-growth aggressiveness using the doubling-time of tumor before everolimus significantly did not impact on the efficacy of everolimus. However, patients with slow tumor growth before everolimus tended to live longer with receiving everolimus and other following regimen such as axitinib.
Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party
Authors: Ali Bazarbachi, Myriam Labopin, Giorgia Battipaglia, Azedine Djabali, Edouard Forcade, William Arcese, Gérard Socié, Didier Blaise, Jakob R. Passweg, Jan J Cornelissen, Patrice Chevallier, Johan Maertens, Nicolaas Schaap, Khowla Hashaishi, Jean Elcheikh, Florent Malard, Jordi Esteve, Arnon Nagler, Mohamad Mohty
Journal: Blood (2018)
Renal dysfunction among patients treated with radiotherapy for locoregionally advanced head and neck cancer.
Authors: Joshua K. Sabari, Keivan Shifteh, Thomas J Ow, Andrew Tassler, Bradley A. Schiff, Madhur Garg, Maury Rosenstein, Catherine Sarta, Hilda Haynes, Yoko Eng, Gregory Rosenblatt, Matthew Abramowitz, Nicolas Schlecht, Michael Prystowsky, Stuart H. Packer, Richard V. Smith, Missak Haigentz
Journal: Journal of Clinical Oncology (2014)

e17026 Background: Radiotherapy (RT), a standard part of the multidisciplinary care for locoregionally advanced head and neck cancer (HNC), is associated with known acute and chronic toxicities. RT is often combined with cisplatin, a nephrotoxic agent, whose effects on renal function in the post-treatment setting of HNC have not been well studied. This study aims to detail the renal function of HNC pts treated with curative-intent RT. Methods: We evaluated 63 pts with T3/T4 laryngeal or pyriform sinus cancers enrolled in a tumor banking study. Data from electronic medical records were used to calculate creatinine clearance (CrCl, Cockcroft-Gault) at t0 pre-RT, t0-6m, and t12m post completion of RT. We also calculated body mass index and obtained serum albumin levels at the above timepoints. Results: There were 44 M and 19 F with 51 laryngeal and 12 pyriform sinus cancers. All 63 pts were treated with RT, and 47 pts were treated with concomitant cisplatin. Baseline mean CrCl for pts treated with and without cisplatin was 90.6 and 81.3 mL/min, respectively [p=0.4]. Mean CrCl decreased in all pts within 6 m of RT initiation and at 12 m post RT (Table). Cisplatin-treated pts had a 46% and 19% mean reduction in CrCl at 6 and 12 m respectively, whereas non-cisplatin treated pts only had a 10% and 7% reduction. Persistent clinically significant renal dysfunction defined as one CKD grade change with CrCl< 60 mL/min at 12 m was observed in 17 pts. Of these pts, 15 were treated with cisplatin (15/47, 32%) and 2 were not treated with cisplatin (2/16, 12.5%) [p=0.2]. Predictors associated with persistent renal dysfunction at 12 m included serum albumin <2.5 [p=0.02] or loss of BMI > 10% [p=0.03] at 0-6 m. Conclusions: Renal dysfunction is common in HNC pts treated with RT, and persistent renal dysfunction may be an important survivorship concern. Although the sample size of our pilot study is small, cisplatin exposure, low serum albumin and loss of BMI may be associated with persistent renal dysfunction, suggesting opportunities for early intervention. n Baseline CrCl 0m Mean CrClmin 0-6m Mean CrClmax 12m Mean ΔCrCl 0-6m (%) Mean ΔCrCl 0-12m (%) Cisplatin 47 90.6 48.6 71.2 46% 19% No Cisplatin 16 81.3 59.6 78.1 10% 7% Total 63 88.5 50.7 72.5 39% 17%
Droplet Digital PCR for the Quantification of Alu Methylation Status in Hematological Malignancies
Authors: Paola Orsini, Luciana Impera, Elisa Parciante, Cosimo Cumbo, Crescenzio Francesco Minervini, Angela Minervini, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Paola Casieri, Giuseppina Tota, Claudia Brunetti, Alessandra Ricco, Paola Carluccio, Giorgina Specchia, Francesco Albano
Journal: Blood (2018)
High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction
Authors: Wynn G. Hunter, Robert W. McGarrah, Jacob P. Kelly, Michel G. Khouri, Damian M. Craig, Carol Haynes, G. Michael Felker, Adrian F. Hernandez, Eric J. Velazquez, William E. Kraus, Svati H. Shah
Journal: Journal of the American College of Cardiology (2019)
Hepatocyte Growth Factor–Secreting Mesothelial Cell Sheets Suppress Progressive Fibrosis in a Rat Model of CKD
Authors: Masatoshi Oka, Sachiko Sekiya, Ryoichi Sakiyama, Tatsuya Shimizu, Kosaku Nitta
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement No effective therapy is currently available to directly address a key feature of CKD progression: interstitial fibrosis leading to a loss of peritubular capillaries (PTCs). One potential antifibrotic candidate, hepatocyte growth factor (HGF), cannot be applied in clinical settings owing to its short t 1/2 in blood and elimination by other organs, such as the liver. The authors describe use of a novel HGF therapy using cell sheet technology: transplantation of transgenic HGF-secreting mesothelial cell sheets to the kidney in a CKD rat model. The HGF-secreting cell sheet directly suppresses interstitial fibrosis for 28 days and prevents loss of peritubular capillaries. Inhibition of CKD progression requires long-term suppression of fibrosis, and cell sheet therapy represents a promising strategy for achieving that goal. Background Although hepatocyte growth factor (HGF) has antifibrotic effects and is involved in angiogenesis and vasodilation, systemic administration of HGF to prevent kidney fibrosis is not a feasible strategy for suppressing interstitial fibrosis in patients with CKD. Methods We investigated a novel therapy involving HGF transgenic cell sheets grown in culture from human mesothelial cells and administered to rats with unilateral ureteral obstruction (UUO). We compared progression of fibrosis in rats with UUO that received one of five interventions: HGF-transgenic mesothelial cell sheets transplanted to the kidney surface, HGF-transgenic mesothelial cell sheets transplanted to thigh, mesotherial cell sheets transplanted to kidney, no sheets, or HGF injections. Results HGF transgenic cell sheets transplanted to the kidney strongly suppressed the induction of myofibroblasts and collagen in the kidney for 28 days; other interventions did not. Additionally, the HGF-secreting cell sheets ameliorated loss of peritubular capillaries and maintained renal blood flow. Conclusions These findings suggest that cell sheet therapy is a novel and promising strategy for inhibiting progressive fibrosis in CKD.
Suppression of GATA3 Binding Drives Selective Abrogation of NOTCH1-MYC Enhancer Activity By Nucleosome Invasion in Thymocyte Development and Leukemia
Authors: Laura Belver, Alexander Y Yang, Daniel Herranz, Aidan Quinn, Francesco G Brundu, Pablo Perez-Duran, Silvia Alvarez, Devya Gurung, Pedro P Rocha, Ramya Raviram, Marissa Rashkovan, Raul Rabadan, Adolfo A. Ferrando
Journal: Blood (2018)
FRI0120 Evaluation of rituximab, tocilizumab and abatacept in a french multicenter rhupus cohort
Authors: G. Laustriat, O. Fogel, D. Wendling, S. Ottaviani, S. Guignard, J. Morel, J.E. Gottenberg, A. Cantagrel
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rhupus, a combination of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus, is a rare entity. Existing epidemiological and therapeutic data are limited. <h3>Objectives</h3> The aim of this study was to describe the therapeutic impact and safety of three biologic therapies: Rituximab, Tocilizumab and Abatacept in a french Rhupus cohort. <h3>Methods</h3> We have set up a transverse observational retrospective and multi-centric study. To be included in the cohort, patients had to present an overlap syndrome fulfilling criterias for rheumatoid arthritis and lupus, and to be treated at least by one of these three therapies. Enrollment has been made with a file available on the CRI website and the analysis of the French RA registers (AIR, REGATE and ORA). Primary endpoint was the median time in therapeutic maintenance for each biological agent. <h3>Results</h3> Forty patients from fifteen rheumatologic centres were included. The main demographic data for these patients are given in table 1. Thirty of them received a treatment with Rituximab, twelve with Tocilizumab and seven with Abatacept. Nine patients received 2 biologics at two different times of the disease. The medians of therapeutic maintenance were 82 months with Rituximab, 48 with Tocilizumab and 55 with Abatacept. The detailed analysis of clinical and biologic parameters revealed differences in effectiveness between therapies: corticosteroid doses decreased more in Rituximab group, VAS activity decreased more in Abatacept group, CRP decreased more in Tocilizumab group. Safety of biologics was similar to the data in literature for RA patients. <h3>Conclusions</h3> This study provides original data on the effectiveness and safety of non-TNF biologics, mostly rituximab, in a large cohort of patients with rhupus. We have not enough patients treated with Tocilizumab and Abatacept to conclude but the therapeutic maintenance of Rituximab in Rhupus is similar to the one usually observed in RA. <h3>Disclosure of Interest</h3> None declared
Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs
Authors: Vittorio Montefusco, Francesca Gay, Stefano Spada, Lorenzo De Paoli, Francesco Di Raimondo, Rossella Ribolla, Caterina Musolino, Francesca Patriarca, Pellegrino Musto, Piero Galieni, Michele Cavo, Stelvio Ballanti, Chiara Nozzoli, Nicola Cascavilla, Dina Ben-Yehuda, Arnon Nagler, Roman Hajek, Massimo Offidani, Anna Marina Liberati, Paolo Corradini, Mario Boccadoro
Journal: Blood (2018)
Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)
Authors: Ahmed Sawas, Hager Elgedawe, George Vlad, Mikel Lipschitz, Pei-Hsuan Chen, Scott J Rodig, Jennifer Kimberly Lue, Changchun Deng, Jennifer E Amengual, Maher Abdul Hay, Karen Khan, Laine E. Atkins, Aishling M. Rada, Larisa Geskin, Owen A. O'Connor
Journal: Blood (2018)
AB0746 Frequency and clinical association of rare antibodies in a large connective tissue disease cohort
Authors: C. Campochiaro, K. Clark, L. Host, A. Sari, S. Nihtyanova, C. Fonseca, C. Denton, V. Ong
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Connective tissue diseases(CTDs) are characterised by the presence of specific antibodies(Abs). These are useful in diagnosis and prognostic stratification. Rare Abs have been reported but their clinical significance is currently not as clear. <h3>Objectives</h3> to assess the diagnosis, and frequency of clinical features within each rare antibody subgroup in our CTD cohort <h3>Methods</h3> The immunology results for 5828 patients obtained over the past 17 years and patients positive for 1 of the rare Abs (Jo-1, PCNA,XR,PL-4,PL-7,PL-12,SRP, Ku,Mi-2,EJ,SL,PmScl,rRNP,Th/To,NuMa-1,OJ and hnRNP) were identified. Diagnosis and frequency of major organ involvement were reported. <h3>Results</h3> 758 patients(12.5%) were positive for at &gt;1 rare Abs. Clinical information confirming a diagnosis of a CTD was available for 514 patients. The most frequent rare Ab in our cohort was PmScl(3.10%). The majority of patients had clinical features of overlap syndromes(33.8%), the 2nd most common diagnosis was systemic sclerosis(SSc)(31.10%). Interstitial lung disease(ILD) was more commonly seen in patients with PL-7+(82.4%), PL-12+(75%), Jo-1+(70.8%) and SRP+(66.7%). ILD was not reported in PCNA+,PL-4+, NuMA-1+and hnRNP+. Pulmonary arterial hypertension(PAH) was most frequently seen in patients with XR+(31.8%). Inflammatory myositis(IM) was found in all Jo1 +and SRP +patients, and in the majority of PL-7+(88.2%) patients. Inflammatory arthritis was commonly reported in patients with PCNA+(57.1%), NuMA-1+(50.0%) and rRNP+(40%). Renal involvement was classified as either glomerulonephritis(GMN) or scleroderma renal crisis(SRC). GMN was more common in patients with rRNP+(60%), PL-4+(45.4%) and PCNA+(42.9%) patients. SRC was diagnosed in patients with SL+(3.2%), PM/Scl+(5.5%) and Th/To+(2.5%) (table 1). <h3>Conclusions</h3> Our data from a large CTD cohort suggest that rare Abs associate with distinct features in particular ILD and inflammatory myositis. A majority of these patients fulfil the criteria for overlap syndrome and SSc. <h3>Disclosure of Interest</h3> None declared
A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study
Authors: Cyrille Hulin, Margaret Macro, Sophie Gourgou, Florence Lachenal, Caroline Bureau Lenoir, Bertrand Arnulf, Denis Caillot, Anne Marie Stoppa, Laure Vincent, Arnaud Jaccard, Philippe Moreau, Aurore Perrot, Mohamad Mohty, Lionel Karlin, Cécile Fohrer, Jean-Richard Eveillard, Choquet Sylvain, Jean Fontan, Xavier Leleu, Olivier Decaux
Journal: Blood (2018)
Basal Polarity Complex Scribble Is Required for Leukemic Initiation and Propagation through Negative Regulation of Apical Polarity Complex Activator Cdc42 and Hypoxia Inducing Factor-1α
Authors: Shailaja N Hegde, Mark J Althoff, Ramesh C. Nayak, Ashley M Wellendorf, Fatima Mohmoud, Gang Huang, Yi Zheng, Maria T Diaz-Meco, Jorge Moscat, Jose A Cancelas
Journal: Blood (2018)
Duodenal-jejunal lining increases postprandial unconjugated bile acid responses and disrupts the bile acid-FXR-FGF19 axis in humans
Authors: Frederik Samuel van Nierop, Charlotte de Jonge, Wim Kulik, Nicole Bouvy, Frank G. Schaap, Steven W. Olde Damink, Sander Rensen, Johannes A. Romijn, Jan Willem M. Greve, Maarten R. Soeters
Journal: Metabolism (2019)
Abstract 13779: The Association Between the Severity of Chronic Obstructive Pulmonary Disease and Presenting Rhythm in Patients With Out-of-hospital Cardiac Arrest
Authors: Asger Granfeldt, Mads Wissenberg, Steen M Hansen, Freddy K. Lippert, Christian Torp-Pedersen, Lars W. Andersen, Erika F. Christensen, Christian F Christiansen
Journal: Circulation (2017)

Introduction: Non-cardiovascular diseases are associated with non-shockable rhythm in out-of-hospital cardiac arrest (OHCA). The low survival rate in OHCA patients with chronic obstructive pulmonar...
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Authors: Rachel J. Cook, Tamara Moyo, Jane L. Liesveld, David A. Rizzieri, Eytan M. Stein, Stephane De Botton, Gail J. Roboz, Mikkael A. Sekeres, Joseph G. Jurcic, Azra Raza, Robert L. Redner, Dale L. Bixby, Jorge E. Cortes, Kristin Stephens, Angela Volkert, Qing Kang, Emmanuelle Di Tomaso, David A. Roth, Carlos E Vigil
Journal: Blood (2018)
Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival
Authors: Ryan J Stubbins, Lauren Lee, Yasser Abou Mourad, Michael J Barnett, Raewyn Broady, Donna L. Forrest, Alina S. Gerrie, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J Nevill, Maryse Power, Kevin Song, Heather J. Sutherland, Cynthia L Toze, Jennifer White, David Sanford
Journal: Blood (2018)
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Authors: Hiddo J L Heerspink, Tom Greene, Hocine Tighiouart, Ron T Gansevoort, Josef Coresh, Andrew L Simon, Tak Mao Chan, Fan Fan Hou, Julia B Lewis, Francesco Locatelli, Manuel Praga, Francesco Paolo Schena, Andrew S Levey, Lesley A Inker, Angel Sevillano, Anne-Lise Kamper, Arjan D. van Zuilen, Barry M. Brenner, Bart Maes, Benno U. Ihle, Brendan Barret, CB Leung, CC Szeto, Christina Fitzner, Christoph Wanner, Claudio Pozzi, Claudio Ponticelli Montagnino, Di Xie, Dick de Zeeuw, Edmund Lewis, Eduardo Verde, Eduardo Gutierrez, Enyu Imai, Fan Fan Hou, Fernando Caravaca, Fernando C. Fervenza, Francesco Locatelli, Francesco Paolo Schena, Fumiaki Kobayashi, Gabriella Moroni, Gavin J. Becker, Gerald J. Beck, Gerald B. Appel, Gershon Frisch, GG van Essen, Giuseppe Maschio, Giuseppe Remuzzi, Giuseppe Montogrino, Hans-Henrik Parving, Hiddo J.L. Heerspink, Hirofumi Makino, Imitiaz Jehan, Jack F.M. Wetzels, James Donadio, Jamie Dwyer, Jan van den Brand, John Kusek, John M. Lachin, Jose Luño, Julia B. Lewis, Jürgen Floege, Kaleab Z. Abebe, KM Chow, Lawrence G. Hunsicker, Lucia del Vecchio, Manno Carlo, Manuel Praga, Marian Goicoechea, Maximilian von Eynatten, Neil Poulter, Nish Chaturvedi, Patrizia Passerini, Paul E. de Jong, Peter J. Blankestijn, Philip Li, Piero Ruggenenti, Pietro Zucchelli, Priscilla S. Kincaid-Smith, Ralf-Dieter Hilgers, Raymond O. Estacio, Richard D. Rohde, Ritsuko Katafuchi, Robert D. Toto, Robert W. Schrier, Roger A. Rodby, Ronald D. Perrone, Sadayoshi Ito, Saulo Klahr, Simeone Andrulli, Svend Strandgaard, Tak Mao Chan, Thierry P. Hannedouche, Thomas Rauen, Tom Greene, Ursula Verdalles, Vlado Perkovic, William Keane
Journal: The Lancet Diabetes & Endocrinology (2019)
AB0363 Rheumatoid arthritis and sickle cell disease: clinical, biological, radiological and therapeutics specific aspects. a retrospective observational study
Authors: L. Stefko-Comte, F. Eymard, A. Habibi, F. Galacteros, M. Michel, X. chevalier, P. bartolucci, S. guignard
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Thanks to medical advances in sickle cell disease (SCD) treatments, practitioners have to be aware of new comorbidities, as rheumatoid arthritis (RA). <h3>Methods</h3> We conducted a retrospective, observational and monocentric study about clinical, biological and radiological specific aspects of RA in SCD patients and studied the impact of anti-rheumatic drugs, comparing the number of SCD flares occuring six months before/after their introduction, using medical files and phone inquiry. <h3>Results</h3> Twenty-three patients were included in this study. Data about RA treatments and SCD flares could be collected for 15 patients. Middle age at RA diagnostic was 32.9 years-old, sexe ratio was 4.75F/1M. 74% of the patients were RF positive, 65% were ACPA positive. 74% of the patients had articular damages. Among them, 100% had severe carpite which appears to be the major radiological expression of RA in SCD patients, occuring sometimes without finger bone erosion. 100% received at least one specific drug for RA, 35% a biotherapy. There was no significant difference in the number of crisis before and after methotrexate introduction (p=1) or anti TNF alpha drugs (p=0.35 IC95% [−1.26;0.51]. Methotrexate had to be stopped for 3 patients because of acute chest syndrome, which did not occur with anti TNF. No infection was noticed. <h3>Conclusions</h3> In conclusion, in SCD, RA occurs sooner in life course and to be more severe with a particular pattern: carpite and tarsite without finger bone erosion. The use of biotherapy appears to be safe, with a close monitoring. <h3>Disclosure of Interest</h3> None declared
Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes
Authors: Leigh Goedeke, Rachel J. Perry, Gerald I. Shulman
Journal: The Annual Review of Pharmacology and Toxicology (2019)

Type 2 diabetes (T2D) is characterized by persistent hyperglycemia despite hyperinsulinemia, affects more than 400 million people worldwide, and is a major cause of morbidity and mortality. Insulin resistance, of which ectopic lipid accumulation in the liver [nonalcoholic fatty liver disease (NAFLD)] and skeletal muscle is the root cause, plays a major role in the development of T2D. Although lifestyle interventions and weight loss are highly effective at reversing NAFLD and T2D, weight loss is difficult to sustain, and newer approaches aimed at treating the root cause of T2D are urgently needed. In this review, we highlight emerging pharmacological strategies aimed at improving insulin sensitivity and T2D by altering hepatic energy balance or inhibiting key enzymes involved in hepatic lipid synthesis. We also summarize recent research suggesting that liver-targeted mitochondrial uncoupling may be an attractive therapeutic approach to treat NAFLD, nonalcoholic steatohepatitis, and T2D.
Abstract 13731: Telephone Cardiopulmonary Resuscitation Process Measures and Survival After Pediatric OHCA
Authors: Daniel Salevitz, Micah Panczyk, Vatsal Chikani, Daniel W Spaite, Taylor A George, Terry Mullins, Vinay Nadkarni, Robert Berg, Silvana Arciniegas Rodriguez, Bentley J Bobrow
Journal: Circulation (2017)

Background: Telephone cardiopulmonary resuscitation (TCPR) is associated with improved patient outcomes after out-of-hospital cardiac arrest (OHCA). Compared with TCPR for adults, little is known a...
Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
Authors: Shaowei Qiu, Andrew J Paterson, Ajay Abraham, Jianbo He, Mansi Shah, Puneet Agarwal, Amanda K Mullen, Hui Li, Mason W Harris, Nicholas R Anderson, Ravi Bhatia
Journal: Blood (2018)
Abstract 17434: Insulin-Like Growth Factor Binding Protein-7 as a Biomarker of Diastolic Dysfunction: Results From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study
Authors: James L Januzzi, Brian Claggett, Jiankang Liu, Amil Shah, Michael Zile, Burkert Pieske, Adriaan Voors, Milton Packer, Parul U Gandhi, Margaret F Prescott, Victor Shi, Martin Lefkowitz, John J McMurray, Scott D Solomon
Journal: Circulation (2017)

Introduction: Insulin-like growth factor binding protein-7 (IGFBP7) is involved in cell cycle arrest with tissue fibrosis, and may be related to diastolic function. We measured IGFBP7 in patients w...